NIPH Clinical Trials Search

UMIN ID: UMIN000000741

Registered date:18/06/2007

Quantification of Epstein-Barr virus DNA in patients undergoing SMILE chemotherapy for stage IV or relapsed/refractory extranodal NK/T-cell lymphoma

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studieduntreated stage IV or relapsed/refractory NK/T-cell lymphoma
Date of first enrollment2007/07/01
Target sample size28
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)SMILE chemotherapy (steroid, methotrexated, ifosfamide, l-asparaginase, etoposide)


Primary OutcomeDisappearance rate of EBV-DNA after two cycles of the SMILE quantified by whole blood method
Secondary OutcomeDisapperance rate of EBV-DNA after completion of intended therapy, prognostic value of EBV-DNA level, comparison between two methods of EBV-DNA quantification (whole blood vs plasma)

Key inclusion & exclusion criteria

Age minimum15years-old
Age maximum69years-old
GenderMale and Female
Include criteria
Exclude criterianone

Related Information


public contact
Name Ritsuro Suzuki
Address Japan
Affiliation Nagoya University School of Medicine Department of HSCT Data Management
scientific contact
Name Kazuo Oshimi
Address 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan Japan
Affiliation Juntendo University School of Medicine Department of Hematology